The VMAT-2 inhibitor tetrabenazine alters effort-related decision making as measured by the T-maze barrier choice task: reversal with the adenosine A2A antagonist MSX-3 and the catecholamine uptake blocker bupropion

• Published in: Psychopharmacology 2015-04, Vol.232 (7), p.1313-1323
• Main Authors: Yohn, Samantha E., Thompson, Christian, Randall, Patrick A., Lee, Christie A., Müller, Christa E., Baqi, Younis, Correa, Mercè, Salamone, John D.
• Format: Article
• Language: English
• Subjects: Adenosine A2 Receptor Antagonists - pharmacology; Animals; Antidepressive Agents - pharmacology; Biomedical and Life Sciences; Biomedicine; Bupropion - pharmacology; Catecholamines - antagonists & inhibitors; Catecholamines - metabolism; Choice Behavior - drug effects; Choice Behavior - physiology; Decision Making - drug effects; Decision Making - physiology; Dopamine Antagonists - pharmacology; Dose-Response Relationship, Drug; Male; Maze Learning - drug effects; Maze Learning - physiology; Neurosciences; Original Investigation; Pharmacology/Toxicology; Psychiatry; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A - physiology; Tetrabenazine - pharmacology; Vesicular Monoamine Transport Proteins - antagonists & inhibitors; Vesicular Monoamine Transport Proteins - physiology; Xanthines - pharmacology
• ISSN: 0033-3158; 1432-2072
• DOI: 10.1007/s00213-014-3766-0

Rationale Depressed people show effort-related motivational symptoms, such as anergia, retardation, lassitude, and fatigue. Animal tests can model these motivational symptoms, and the present studies characterized the effort-related effects of the vesicular monoamine transport (VMAT-2) inhibitor tetrabenazine. Tetrabenazine produces depressive symptoms in humans and, at low doses, preferentially depletes dopamine. Objectives The current studies investigated the effects of tetrabenazine on effort-based decision making using the T-maze barrier task. Methods Rats were tested in a T-maze in which the choice arms of the maze contain different reinforcement densities, and under some conditions, a vertical barrier was placed in the high-density arm to provide an effort-related challenge. The first experiment assessed the effects of tetrabenazine under different maze conditions: a barrier in the arm with 4 food pellets and 2 pellets in the no barrier arm (4–2 barrier), 4 pellets in one arm and 2 pellets in the other with no barrier in either arm (no barrier), and 4 pellets in the barrier arm with no pellets in the other (4–0 barrier). Results Tetrabenazine (0.25–0.75 mg/kg IP) decreased selection of the high cost/high reward arm when the barrier was present, but had no effect on choice under the no barrier and 4–0 barrier conditions. The effects of tetrabenazine on barrier climbing in the 4–2 condition were reversed by the adenosine A 2A antagonist MSX-3 and the catecholamine uptake inhibitor and antidepressant bupropion. Conclusions These studies have implications for the development of animal models of the motivational symptoms of depression and other disorders.